MTAP and glioblastoma: Defying the generalized conclusion that bevacizumab does not impact survival in GBM, Japanese investigators uncovered a survival benefit for bevacizumab in MGMT-unmethylated, CDKN2A-deficient GBM,13 plausibly by blocking autocrine stimulation through the vascular endothelial growth factor (VEGFA)–KDR–PI3K pathway.14 Mechanistically, MTAP is also synthetic lethal with GARFT.